Comprehensive Stock Comparison

Compare Seer, Inc. (SEER) vs BiomX Inc. (PHGE) Stock

Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.

Tickers 2 / 10100+ Metrics

Selected Stocks

Add up to 10 tickers. Use presets or search to get started.

2 / 10
Try these comparisons:

Quick Verdict

CategoryWinnerWhy
Stability / SafetySEER logoSEERBeta 0.52 vs PHGE's 0.93, lower leverage
DividendsTieNeither pays a meaningful dividend
Momentum (1Y)SEER logoSEER-9.3% vs PHGE's -48.8%
Efficiency (ROA)SEER logoSEER-25.7% ROA vs PHGE's -142.8%, ROIC -21.3% vs -305.2%
Bottom line: SEER leads in 3 of 4 categories, making it the stronger pick for investors who prioritize capital preservation and lower volatility and recent price momentum and sentiment. As direct sector peers, they can serve as alternatives in the same portfolio allocation.

Who Each Stock Is For

Income & stability

Growth exposure

Long-term compounding (10Y)

Sleep-well-at-night portfolio

Defensive / Recession hedge

Business Model

What each company does and how it makes money

SEERSeer, Inc.
Healthcare

Seer is a life sciences company that develops and commercializes proteomics technology to analyze proteins for research and drug discovery. It generates revenue primarily from sales of its Proteograph Product Suite — an integrated system of consumables, automation instruments, and software — to academic institutions, biopharma companies, and research laboratories. The company's competitive advantage lies in its proprietary technology platform that enables deep, unbiased proteomic analysis at scale, which could accelerate biomarker discovery and therapeutic development.

PHGEBiomX Inc.
Healthcare

BiomX is a clinical-stage biotechnology company developing targeted phage therapies — viruses that kill specific harmful bacteria — for chronic diseases and skin conditions. It generates no commercial revenue yet but is funded through equity offerings and partnerships to advance its pipeline, which includes therapies for cystic fibrosis, inflammatory bowel diseases, and atopic dermatitis. The company's key advantage is its proprietary platform for discovering and engineering natural phages that precisely target disease-causing bacteria while sparing beneficial microbes.

Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SEERSeer, Inc.
FY 2023
Grant
100.0%$1M
PHGEBiomX Inc.

Segment breakdown not available.

Financial Metrics Comparison

Side-by-side fundamentals across 2 stocks. BestLagging

Financial Scorecard

SEER logoSEER 4PHGE logoPHGE 0
Financial MetricsSEER logoSEER1/1 metrics
Valuation MetricsTie1/2 metrics
Profitability & EfficiencySEER logoSEER7/8 metrics
Total ReturnsSEER logoSEER5/6 metrics
Risk & VolatilitySEER logoSEER2/2 metrics
Analyst Outlook0/0 metrics

SEER leads in 4 of 6 categories — strongest in Financial Metrics and Profitability & Efficiency. 1 category is tied.

Financial Metrics (TTM)

SEER and PHGE operate at a comparable scale, with $16M and $0 in trailing revenue.

MetricSEER logoSEERSeer, Inc.PHGE logoPHGEBiomX Inc.
RevenueTrailing 12 months$16M$0
EBITDAEarnings before interest/tax-$76M-$6M
Net IncomeAfter-tax profit-$79M-$37M
Free Cash FlowCash after capex-$46M-$28M
Gross MarginGross profit ÷ Revenue+40.7%
Operating MarginEBIT ÷ Revenue-5.2%
Net MarginNet income ÷ Revenue-4.9%
FCF MarginFCF ÷ Revenue-2.8%
Rev. Growth (YoY)Latest quarter vs prior year+4.5%
EPS Growth (YoY)Latest quarter vs prior year+8.6%-6.5%
SEER leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

MetricSEER logoSEERSeer, Inc.PHGE logoPHGEBiomX Inc.
Market CapShares × price$103M$82.8B
Enterprise ValueMkt cap + debt − cash$88M$82.8B
Trailing P/EPrice ÷ TTM EPS-1.33x-4.29x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue7.40x
Price / BookPrice ÷ Book value/share0.35x3427.64x
Price / FCFMarket cap ÷ FCF
Evenly matched — SEER and PHGE each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

SEER delivers a -29.2% return on equity — every $100 of shareholder capital generates $-29 in annual profit, vs $-4 for PHGE. SEER carries lower financial leverage with a 0.08x debt-to-equity ratio, signaling a more conservative balance sheet compared to PHGE's 0.40x. On the Piotroski fundamental quality scale (0–9), SEER scores 4/9 vs PHGE's 3/9, reflecting mixed financial health.

MetricSEER logoSEERSeer, Inc.PHGE logoPHGEBiomX Inc.
ROE (TTM)Return on equity-29.2%-3.6%
ROA (TTM)Return on assets-25.7%-142.8%
ROICReturn on invested capital-21.3%-3.1%
ROCEReturn on capital employed-25.9%-159.9%
Piotroski ScoreFundamental quality 0–943
Debt / EquityFinancial leverage0.08x0.40x
Net DebtTotal debt minus cash-$15M-$8M
Cash & Equiv.Liquid assets$41M$18M
Total DebtShort + long-term debt$26M$10M
Interest CoverageEBIT ÷ Interest expense-36.86x
SEER leads this category, winning 7 of 8 comparable metrics.

Total Returns (with DRIP)

A $10,000 investment in SEER five years ago would be worth $427 today (with dividends reinvested), compared to $47 for PHGE. Over the past 12 months, SEER leads with a -9.3% total return vs PHGE's -48.8%. The 3-year compound annual growth rate (CAGR) favors SEER at -28.2% vs PHGE's -59.1% — a key indicator of consistent wealth creation.

MetricSEER logoSEERSeer, Inc.PHGE logoPHGEBiomX Inc.
YTD ReturnYear-to-date+1.6%+194.4%
1-Year ReturnPast 12 months-9.3%-48.8%
3-Year ReturnCumulative with dividends-62.9%-93.2%
5-Year ReturnCumulative with dividends-95.7%-99.5%
10-Year ReturnCumulative with dividends-96.7%-99.7%
CAGR (3Y)Annualised 3-year return-28.2%-59.1%
SEER leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

SEER is the less volatile stock with a 0.52 beta — it tends to amplify market swings less than PHGE's 0.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SEER currently trades 76.8% from its 52-week high vs PHGE's 42.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSEER logoSEERSeer, Inc.PHGE logoPHGEBiomX Inc.
Beta (5Y)Sensitivity to S&P 5000.52x0.93x
52-Week HighHighest price in past year$2.41$14.71
52-Week LowLowest price in past year$1.62$1.56
% of 52W HighCurrent price vs 52-week peak+76.8%+42.8%
RSI (14)Momentum oscillator 0–10042.751.0
Avg Volume (50D)Average daily shares traded239K1.3M
SEER leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

MetricSEER logoSEERSeer, Inc.PHGE logoPHGEBiomX Inc.
Analyst RatingConsensus buy/hold/sellHold
Price TargetConsensus 12-month target
# AnalystsCovering analysts4
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+11.4%0.0%
Insufficient data to determine a leader in this category.

Historical Charts

Charts are rendered on first load. Hover for details.

Chart 1Total Return — 5 Years (Rebased to 100)

StockDec 20Mar 26Change
Seer, Inc. (SEER)1003.06-96.9%
BiomX Inc. (PHGE)1000.36-99.6%

Seer, Inc. (SEER) returned -96% over 5 years vs BiomX Inc. (PHGE)'s -100%.

Chart 2Revenue Growth — 10 Years

Stock20172024Change
Seer, Inc. (SEER)$0.00$14M
BiomX Inc. (PHGE)$0.00$0.00

BiomX Inc.'s revenue grew from $0M (2017) to $0M (2024) — a 0.0% CAGR.

Chart 3EPS Growth — 10 Years

Stock20172024Change
Seer, Inc. (SEER)-0.29-1.39-379.3%
BiomX Inc. (PHGE)-3.27-1.47+55.0%

BiomX Inc.'s EPS grew from $-3.27 (2017) to $-1.47 (2024).

Chart 4Free Cash Flow — 5 Years

2021
$-53M
$-31M
2022
$-71M
$-29M
2023
$-66M
$-21M
2024
$-50M
$-37M
Seer, Inc. (SEER)BiomX Inc. (PHGE)

Seer, Inc. generated $-50M FCF in 2024 (+7% vs 2021). BiomX Inc. generated $-37M FCF in 2024 (-18% vs 2021).

Loading custom metrics...

SEER vs PHGE: Frequently Asked Questions

7 questions · data-driven answers · updated daily

01

Is SEER or PHGE a better buy right now?

Analysts rate Seer, Inc. (SEER) a "Hold" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — SEER or PHGE?

Over the past 5 years, Seer, Inc. (SEER) delivered a total return of -95.7%, compared to -99.5% for BiomX Inc. (PHGE). A $10,000 investment in SEER five years ago would be worth approximately $427 today (assuming dividends reinvested). Over 10 years, the gap is even starker: SEER returned -96.7% versus PHGE's -99.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — SEER or PHGE?

By beta (market sensitivity over 5 years), Seer, Inc. (SEER) is the lower-risk stock at 0.52β versus BiomX Inc.'s 0.93β — meaning PHGE is approximately 78% more volatile than SEER relative to the S&P 500. On balance sheet safety, Seer, Inc. (SEER) carries a lower debt/equity ratio of 8% versus 40% for BiomX Inc. — giving it more financial flexibility in a downturn.

04

Which has better profit margins — SEER or PHGE?

BiomX Inc. (PHGE) is the more profitable company, earning 0.0% net margin versus -620.9% for Seer, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHGE leads at 0.0% versus -717.7% for SEER. At the gross margin level — before operating expenses — SEER leads at 49.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

05

Which pays a better dividend — SEER or PHGE?

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

06

Is SEER or PHGE better for a retirement portfolio?

For long-horizon retirement investors, Seer, Inc. (SEER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.52)). Both have compounded well over 10 years (SEER: -96.7%, PHGE: -99.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

07

What are the main differences between SEER and PHGE?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.

📊
Stocks Like

SEER

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 24%
Run This Screen
📊
Stocks Like

PHGE

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen